Principal Financial Group Inc. Trims Stake in Esperion Therapeutics, Inc. $ESPR
Principal Financial Group Inc. significantly reduced its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 51.7% during the third quarter, now owning 190,056 shares valued at $504,000. This move comes as other institutional investors have modified their positions, with insider Benjamin Halladay also selling shares. Esperion Therapeutics' stock is currently trading down 1.4% and has received mixed ratings from analysts, with a consensus of "Moderate Buy" and an average target price of $8.00.
Esperion settles another lawsuit to keep generic versions of popular drug off shelves
Esperion Therapeutics has settled another patent infringement lawsuit, this time with Alkem Laboratories, to prevent generic versions of its cholesterol-lowering drug bempedoic acid (Nexletol) from entering the market before patent expiration. The company, which gained FDA clearance for bempedoic acid in 2020, has previously reached similar settlements with several other generic manufacturers. Esperion still has pending lawsuits against additional pharmaceutical companies that filed Abbreviated New Drug Applications (ANDAs) for the drug.
Esperion to Participate in The 2026 Citizens Life Sciences Conference
Esperion (NASDAQ: ESPR) announced its participation in the 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET. The webcast will be available live and as a replay on the company's investor relations website for 90 days. Esperion is a biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, currently marketing two oral non-statin therapies for high LDL-C.
Esperion to Participate in The 2026 Citizens Life Sciences Conference
Esperion Therapeutics, Inc. announced its participation in the 2026 Citizens Life Sciences Conference, scheduled for March 11, 2026, at 8:25 a.m. ET. A live webcast will be available on Esperion's investor and media website, with a replay accessible for approximately 90 days afterward. Esperion is a commercial-stage biopharmaceutical company focused on developing and delivering innovative cardiovascular and rare disease therapies.
Esperion Therapeutics (ESPR) has signed a settlement agreement with a fifth generic drug applicant.
Esperion Therapeutics has entered into a settlement agreement with a fifth generic drug applicant, which prevents the generic marketing of its drugs Nexletol and Nexlizet before April 19, 2040. This agreement strengthens the market exclusivity for Esperion's key products, expected to positively impact the company's future revenue prospects. The drugs are crucial for treating hypercholesterolemia.
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040
Esperion announced a settlement agreement with Alkem Laboratories Ltd., preventing Alkem from marketing generic versions of NEXLETOL and NEXLIZET in the U.S. before April 19, 2040. This resolves one patent litigation, while similar lawsuits against other generic manufacturers are ongoing. Esperion, a biopharmaceutical company, continues to develop and commercialize cardiometabolic and rare disease therapies, leveraging its expertise in ACLY biology.
Generic rival agrees not to copy Esperion cholesterol drugs until 2040
Esperion announced a settlement with Alkem Laboratories, resolving patent litigation surrounding their cholesterol-lowering drugs, NEXLETOL and NEXLIZET. Under the terms, Alkem will not market generic versions in the U.S. until April 19, 2040, although litigation with four other generic drug filers is still pending. This agreement enhances the patent narrative for Esperion's key products, offering extended market exclusivity.
Esperion Reaches Settlement Agreement with Fifth ANDA Filer
Esperion has reached a settlement agreement with Alkem Laboratories Ltd. regarding patent litigation for its drugs NEXLETOL and NEXLIZET. Alkem has agreed not to market generic versions of these drugs in the U.S. before April 19, 2040, barring specific customary circumstances. Litigation continues against other defendants concerning generic versions of these products.
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by Wall Street Zen to "Hold"
Wall Street Zen has downgraded Esperion Therapeutics (NASDAQ:ESPR) from "buy" to "hold," despite the broader analyst consensus remaining a "Moderate Buy" with an $8.00 price target. The company's stock opened at $3.43, and has experienced insider selling totaling 15,543 shares in the last 90 days, while institutional investors hold approximately 47% of the stock. Esperion Therapeutics is a biopharmaceutical company focused on developing therapies for atherosclerotic cardiovascular disease.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion announced it granted 40,200 restricted stock units (RSUs) to 11 new employees under its 2017 Inducement Equity Incentive Plan, in accordance with NASDAQ Listing Rule 5635(c)(4). These RSUs are an inducement for new employment, with vesting commencing after one year and continuing quarterly. The plan is exclusively for new hires or those rejoining after a bona fide period of non-employment.
New hires at Esperion receive 40,200 restricted stock units as hiring incentive
Esperion (NASDAQ: ESPR) announced the grant of 40,200 restricted stock units (RSUs) to 11 newly hired employees under its 2017 Inducement Equity Incentive Plan. This grant, made on February 10, 2026, aligns with NASDAQ Rule 5635(c)(4). The RSUs will vest 25% after one year, with the remaining 75% vesting in twelve equal quarterly installments, contingent on continued employment.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) announced on February 11, 2026, that it granted 11 new employees 40,200 restricted stock units (RSUs) under its 2017 Inducement Equity Incentive Plan. These grants are specifically for new hires as an inducement to employment, aligning with NASDAQ Listing Rule 5635(c)(4). The RSUs will vest over time, contingent on continued employment, with 25% vesting after one year and the remaining 75% in quarterly installments.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion announced granting 40,200 restricted stock units (RSUs) to 11 new employees on February 10, 2026, under its 2017 Inducement Equity Incentive Plan. These grants are material inducements for their employment, complying with NASDAQ Listing Rule 5635(c)(4). The RSUs will vest over approximately four years, contingent on continuous employment.
Esperion Therapeutics: A Surge in Profit Forecasts Signals a Pivotal Year Ahead
Esperion Therapeutics is poised for a transformative 2026, driven by a significant upward revision in its quarterly earnings per share forecast from Zacks Research, strong year-over-year revenue growth, and a solid cash position. Key upcoming catalysts include the potential inclusion of bempedoic acid into U.S. treatment guidelines and international expansion, particularly with anticipated revenue from Japan and regulatory decisions in other markets. The company is also pursuing a long-term "Vision 2040" to diversify into rare kidney and liver diseases, with investors awaiting final audited financial results for Q4 and full-year 2025.
Zacks Research Issues Optimistic Forecast for ESPR Earnings
Zacks Research significantly increased its Q4 2025 EPS estimate for Esperion Therapeutics (NASDAQ:ESPR) to $0.32, up from $0.02, and issued optimistic forecasts for 2026-2027, signaling a potential path to profitability. Despite some mixed analyst sentiment, the company holds a "Moderate Buy" consensus rating with an average price target of $7.20. Esperion Therapeutics' stock currently trades around $3.42, and institutions own approximately 47% of its shares.
Zacks Research Analysts Reduce Earnings Estimates for ESPR
Zacks Research has lowered its Q3 2026 earnings per share estimate for Esperion Therapeutics (NASDAQ:ESPR) to $0.01 from $0.04, and projects FY2027 EPS of $0.26. This adjustment comes despite Esperion recently beating revenue expectations but missing EPS estimates in its last quarterly report. The biopharmaceutical company currently holds a "Moderate Buy" consensus rating with an average price target of $7.20.
Esperion Therapeutics (NASDAQ:ESPR) Raised to "Buy" at Wall Street Zen
Wall Street Zen upgraded Esperion Therapeutics (NASDAQ:ESPR) from a "hold" to a "buy" rating, reflecting a "Moderate Buy" consensus from analysts with an average price target of $7.20. Despite missing EPS estimates, the biopharmaceutical company beat revenue expectations. Insider selling and institutional investment details were also reported, with institutional investors owning approximately 47.4% of the company.
3,000,000 Shares in Esperion Therapeutics, Inc. $ESPR Bought by AIGH Capital Management LLC
AIGH Capital Management LLC recently purchased 3,000,000 shares of Esperion Therapeutics (ESPR) for approximately $7.95 million, making it a significant holding in their portfolio. This investment positions AIGH Capital Management as a notable owner of Esperion, a biopharmaceutical company focused on cardiovascular disease therapies. Despite some insider selling, analysts maintain a "Moderate Buy" rating for ESPR, projecting potential upside from its current trading price.
Esperion Therapeutics general counsel sells $4.9k in stock By Investing.com
Benjamin Looker, General Counsel at Esperion Therapeutics Inc., sold 1,689 shares for $4,867 to cover tax obligations. The company, with a $700.4 million market cap, is not profitable but has seen its stock surge 159% in six months. Recent positive announcements include a $90 million payment from a Japanese drug launch and Canadian approval for another cholesterol drug.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by Brokerages
Esperion Therapeutics (NASDAQ:ESPR) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month price target of $7.20. Despite missing EPS expectations in its latest quarter, the company exceeded revenue forecasts. Insider trading activity included a sale by the CFO and overall insider selling, with institutional investors also adjusting their stakes.
Esperion Therapeutics general counsel sells $4.9k in stock
Esperion Therapeutics' General Counsel, Benjamin Looker, sold 1,689 shares of common stock for $4,867 to cover tax obligations. This transaction comes as the company, despite operating with significant debt and not being profitable, has seen its stock surge 159% in the past six months. Recent positive developments include a $90 million payment from the launch of NEXLETOL in Japan and Health Canada approval for Nilemdo, alongside favorable analyst ratings highlighting the potential of its cholesterol-lowering medications.
What is HC Wainwright's Estimate for ESPR FY2025 Earnings?
HC Wainwright has increased its FY2025 EPS estimate for Esperion Therapeutics (NASDAQ:ESPR) to ($0.15) from ($0.42), maintaining a "Buy" rating and a $16.00 price target. This revised forecast is more optimistic than the consensus, suggesting a quicker path to profitability for the biopharmaceutical company. Esperion's shares are currently trading around $3.23, with an average analyst price target of $7.20, and the company recently reported mixed quarterly results, missing EPS but exceeding revenue estimates.
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 6.3% - Here's Why
Esperion Therapeutics (NASDAQ:ESPR) shares fell 6.3% on Monday, with trading volume significantly below average. Despite missing EPS estimates, the company exceeded revenue expectations. Analysts generally maintain a "Moderate Buy" rating with an average price target of $7.20.
Esperion Therapeutics Faces Financial Challenges Amid Market Uncertainty
Esperion Therapeutics Inc. (ESPR) is facing significant financial challenges, with its stock declining amid market uncertainty. The company reported a substantial loss and increased operating costs, raising concerns about its long-term viability and investor confidence. Analysts are scrutinizing the strategic direction and management's ability to navigate these hurdles, especially after recent FDC ruling setbacks.
Esperion Projects FY2025 U.S. Net Product Sales Growth Of 35% To 38%; Stock Up
Esperion Therapeutics (ESPR) reported strong preliminary financial results for full-year 2025, with U.S. net product sales projected to grow 35% to 38% to $156 million to $160 million, driven by their therapies NEXLETOL and NEXLIZET. Total revenue is expected to increase 20% to 23%, reaching $400 million to $408 million. The company also unveiled its "Vision 2040" strategy, aiming to become an innovation-driven global pharmaceutical leader in cardiometabolic disease prevention.
Esperion Reports $156-$160 Million in 2025 Sales, Unveils Vision 2040 Strategy
Esperion forecasts U.S. net product sales between $156 million and $160 million for 2025, a 35% to 38% increase from 2024, and anticipates total revenues of $400 million to $408 million, marking a 20% to 23% rise. The company also introduced its Vision 2040 strategy, aiming for global leadership in cardiovascular disease prevention with five blockbuster products, and plans to expand through sales, marketing, and the launch of two new triple combination products. Analyst price targets for Esperion (ESPR) range from $1.72 to $16.00, with an average of $6.94 and a "Moderate Buy" consensus.
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Esperion announced strong preliminary full-year 2025 financial results, including $156-$160 million in U.S. net product sales and $400-$408 million in total revenue. The company introduced its "Vision 2040" growth strategy, aiming to become a global pharmaceutical leader with multiple products in cardiometabolic and rare hepatic/renal diseases. Key initiatives include expanding its commercial strategy for NEXLETOL/NEXLIZET, global market expansion, and advancing its ACLY-focused pipeline with new therapeutic candidates like ESP-2001.
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Esperion announced preliminary financial results for full-year 2025, reporting $156 to $160 million in U.S. net product sales and total revenue of $400 to $408 million. The company introduced its "Vision 2040" strategy, aiming to expand its cardiometabolic franchise globally, diversify into rare hepatic and renal diseases, and develop a multi-product portfolio with at least five marketed products. Esperion also provided its 2026 operating expense outlook and highlighted advancements in its commercial strategy, global partnerships, and R&D pipeline, including the nomination of ESP-2001 for primary sclerosing cholangitis.
Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month High - Here's Why
Esperion Therapeutics (NASDAQ:ESPR) recently reached a new 52-week high of $4.18, with significant trading volume. The biopharmaceutical company has a "Moderate Buy" consensus rating from analysts, with price targets ranging from $9 to $16. Despite missing EPS estimates, Esperion surpassed revenue expectations and has a market cap of approximately $922 million.
Esperion Therapeutics gets Untitled Letter from FDA over Nexlizet ad
Esperion Therapeutics has received an Untitled Letter from the FDA for its Nexlizet ad, citing false or misleading exclusivity claims and visual distractions from safety warnings. The FDA's Office of Prescription Drug Promotion flagged the ad's claim that Nexlizet is the "only nonstatin" for statin-intolerant patients and criticized the use of cartoon "lipid lurkers" as distracting. Esperion has 15 working days to respond to the FDA's concerns.
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health
Esperion, a pharmaceutical company, is expanding its focus beyond cardiovascular health into new disease areas while continuing its commitment to patients with statin intolerance. The company's CEO, Sheldon Koenig, discussed their advancements in bempedoic acid for statin-intolerant patients, supported by updated European guidelines, and introduced a new lead compound for Primary Sclerosing Cholangitis (PSC), a rare orphan liver disease. Esperion aims to develop life-saving medications and is formulating a "Vision 2040" strategy for its future direction.
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
Esperion announced its participation in J.P. Morgan’s 44th Annual Healthcare Conference on January 14, 2025. The company will present and engage in a fireside chat, with a live webcast available on their investor website. Esperion is a biopharmaceutical company focused on innovative cardiometabolic and rare disease therapies, with two commercialized oral therapies for LDL-C and a pipeline targeting other conditions.
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
Esperion (NASDAQ: ESPR) announced its participation in J.P. Morgan’s 44th Annual Healthcare Conference, where company representatives will present and engage in a fireside chat on January 14, 2025. A live webcast and subsequent replay will be available on Esperion's investor website. The biopharmaceutical company is known for developing and commercializing therapies for cardiometabolic and rare/orphan diseases, including two non-statin therapies for LDL-C levels.
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
Esperion (NASDAQ: ESPR) announced its participation in J.P. Morgan’s 44th Annual Healthcare Conference on January 14, 2025, with a presentation and fireside chat at 2:15 p.m. PT/5:15 p.m. ET. A live webcast and replay will be available on the company's investor and media section. Esperion is a biopharmaceutical company focused on innovative cardiometabolic and rare/orphan disease therapies.
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by Wall Street Zen to "Buy" Rating
Wall Street Zen has upgraded Esperion Therapeutics (NASDAQ:ESPR) from "hold" to "buy," aligning with other firms and contributing to a "Moderate Buy" consensus with an average price target of $7.20. Despite missing EPS estimates in its latest quarter, the company surpassed revenue expectations, trading around $3.71 with a market cap of $887 million. Insider selling by CFO Benjamin Halladay was noted, although institutional ownership stands at nearly 47.39%.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages
Esperion Therapeutics, Inc. (NASDAQ:ESPR) has received an average "Moderate Buy" recommendation from eight brokerage firms, with an average one-year price target of $7.20. The company reported a Q4 EPS of ($0.16), missing consensus estimates, but revenue topped expectations at $87.31 million. Insider activity shows CFO Benjamin Halladay sold 7,337 shares, while institutions collectively hold 47.39% of the stock.
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
Esperion's bempedoic acid has been recommended as a first-line treatment for lowering LDL-C in patients with Peripheral Artery Disease (PAD) and diabetes, according to the 2025 American College of Cardiology (ACC) Scientific Statement. The recommendation highlights the drug's proven cardiovascular and limb benefits, including a 36% reduction in major adverse limb events in patients with pre-existing PAD, reinforcing its role in aggressive LDL-C lowering strategies. This endorsement strengthens Esperion's position ahead of forthcoming U.S. dyslipidemia treatment guidelines.
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
Esperion's bempedoic acid has been recommended as a first-line therapy for LDL-C lowering in patients with peripheral artery disease (PAD) and diabetes by the 2025 American College of Cardiology (ACC) Scientific Statement. This recommendation highlights the drug's proven cardiovascular and limb benefits, emphasizing its role in aggressive LDL-C lowering for high-risk populations. The company anticipates inclusion in forthcoming U.S. dyslipidemia treatment guidelines in early 2026.
Esperion's Bempedoic Acid Recognized by ACC as Effective LDL-C Lowering Therapy for Patients with PAD and Diabetes
Esperion announced that the American College of Cardiology (ACC) has recognized bempedoic acid as a first-line therapy for lowering LDL cholesterol in patients with peripheral artery disease and diabetes, highlighting its proven cardiovascular and limb benefits. This endorsement in the 2025 ACC Scientific Statement underscores the drug's role in aggressive LDL-C reduction for high-risk patients and is expected to influence future dyslipidemia treatment guidelines. The company's CEO, Sheldon Koenig, expressed confidence in bempedoic acid's contribution to cardiovascular risk reduction.
Esperion’s Bempedoic Acid Receives Recommendation in 2025
Esperion's bempedoic acid has been recommended as a first-line, evidence-based therapy for LDL-C lowering in patients with peripheral artery disease and diabetes, according to the 2025 American College of Cardiology (ACC) Scientific Statement. The drug has shown significant cardiovascular and limb benefits, including a 36% reduction in major adverse limb events in patients with pre-existing PAD during the CLEAR Outcomes trial. This recommendation reinforces the drug's role in aggressive LDL-C lowering strategies and is anticipated to influence forthcoming U.S. dyslipidemia treatment guidelines.
New pill cuts serious limb risks for diabetics with artery disease, ACC says
Esperion's bempedoic acid (NEXLIZET/NEXLETOL) has been recommended by the 2025 ACC Scientific Statement for managing peripheral artery disease (PAD) in adults with diabetes, specifically for LDL-C lowering. The therapy, when added to maximally tolerated statins, demonstrated a 36% reduction in major adverse limb events (MALE) compared to placebo in the CLEAR Outcomes trial. This endorsement reinforces the drug's role in cardiovascular risk reduction and is anticipated to influence future U.S. dyslipidemia guidelines.
Esperion Therapeutics (NASDAQ:ESPR) CFO Benjamin Halladay Sells 7,337 Shares
Esperion Therapeutics CFO Benjamin Halladay recently sold 7,337 shares of the company stock, reducing his stake by 1.55%. This transaction followed Esperion's Q3 earnings report, where the company missed EPS estimates but topped revenue forecasts. The stock traded up after the news, and analysts have a "Moderate Buy" rating with an average price target of $7.20.
Esperion Therapeutics Executives Sell Shares to Satisfy Tax Obligations
Several executives at Esperion Therapeutics (ESPR) recently sold portions of their common stock to meet tax obligations on vested restricted stock units. Benjamin Looker, General Counsel, sold 6,517 shares for $23,897, while CFO Benjamin Halladay sold 7,337 shares for $26,904. President and CEO Sheldon L. Koenig sold 48,244 shares for $177,200.
Esperion Therapeutics (NASDAQ:ESPR) General Counsel Sells $23,917.39 in Stock
Esperion Therapeutics' General Counsel, Benjamin Looker, sold 6,517 shares of ESPR stock on December 17th, totaling $23,917.39 and reducing his position by 1.66%. The company recently reported a quarterly EPS beat on revenue but missed on consensus earnings, with analysts maintaining a "Moderate Buy" rating and an average price target of $7.20. The stock is currently trading at $3.80, with a market capitalization of approximately $908 million.
Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month High - Should You Buy?
Esperion Therapeutics (NASDAQ:ESPR) recently hit a new 52-week high of $4.08, driven by strong trading volume. Despite missing EPS estimates, the company exceeded revenue forecasts and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $7.33. Institutional investors hold nearly half of the stock.
Esperion’s Stock Surge: Opportunity Knocks?
Esperion Therapeutics Inc. (ESPR) stock surged by over 7% following favorable news including an "Overweight" rating from Piper Sandler, the launch of cholesterol-lowering drug NEXLETOL in Japan by partner Otsuka Pharmaceutical, and Health Canada's approval of NILEMDO. These developments signify strong strategic moves and financial gains, positioning Esperion for potential long-term growth in the cardiovascular treatment market. The company, despite profit challenges, shows a strong gross margin and a forward-looking approach with its promising product pipeline and international expansion.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion announced inducement grants to three new employees, including Chief Commercial Officer John Harlow, under its 2017 Inducement Equity Incentive Plan. These grants consist of non-qualified stock options to purchase 380,000 shares and 435,536 restricted stock units, with both options and RSUs linked to continued employment with Esperion. The awards were made in accordance with NASDAQ Listing Rule 5635(c)(4) and aim to incentivize the new hires.
Esperion announces inducement grants under Nasdaq Listing Rule
Esperion Therapeutics, Inc. has announced inducement grants in accordance with Nasdaq Listing Rule. This news is reserved for members of MarketScreener. The company specializes in developing and commercializing oral, once-daily, non-statin medicines for patients with elevated low-density lipoprotein cholesterol, including products like NEXLETOL and NEXLIZET.
Esperion Grants Stock Options and RSUs to New Chief Commercial Officer and Employees
Esperion (NASDAQ: ESPR) has granted 380,000 non-qualified stock options and 435,536 restricted stock units (RSUs) to three new employees, including newly appointed Chief Commercial Officer John Harlow. These awards, made under Esperion’s 2017 Inducement Equity Incentive Plan, are intended to attract and retain new talent and will vest over time contingent on continued employment. The move aims to align employee interests with shareholder value and enhance leadership, though the substantial awards could raise questions about executive compensation.
Esperion (NASDAQ: ESPR) awards 380K options, 435,536 RSUs in inducement grants
Esperion (NASDAQ: ESPR) announced inducement equity grants on December 4, 2025, under its 2017 Inducement Equity Incentive Plan. The company awarded 380,000 non-qualified stock options and 435,536 restricted stock units (RSUs), with newly appointed Chief Commercial Officer John Harlow receiving a significant portion of these. The options have an exercise price of $3.79 per share, matching the closing price on the grant date, and both options and RSUs vest over time, subject to continued employment.
